| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Retosiban (GSK-221149; GSK-221149A) is a novel, potent, orally bioactive, and selective, sub-nanomolar oxytocin receptor antagonist with Ki of 0.65 nM and >1400-fold selectivity over the related vasopressin receptors. The procontractile effect of stretch on the human myometrium is inhibited by retisiban. Retosiban inhibited the stimulation of human myometrial contractility induced by stretch. One possible method for preventing preterm birth in multiple pregnancies is the use of retisiban treatment. GlaxoSmithKline is developing the medication Retosiban to treat premature labor. It has been demonstrated that in the anesthetized rat, GSK221149A inhibits oxytocin-induced uterine contractions.
| Targets |
Oxytocin ( IC50 = 0.65 nM )
|
|---|---|
| References | |
| Additional Infomation |
Retosiban is a dipeptide.
Retosiban has been used in trials studying the treatment of Premature Labor and Obstetric Labour, Premature. Drug Indication Treatment of spontaneous preterm labour |
| Molecular Formula |
C27H34N4O5
|
|---|---|
| Molecular Weight |
494.58266
|
| Exact Mass |
494.253
|
| Elemental Analysis |
C, 65.57; H, 6.93; N, 11.33; O, 16.17
|
| CAS # |
820957-38-8
|
| Related CAS # |
(S)-Retosiban
|
| PubChem CID |
11340891
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
2.191
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
36
|
| Complexity |
819
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
[C@H](C1=COC(C)=N1)(N1C(=O)[C@@H](C2CC3C=CC=CC=3C2)NC(=O)[C@H]1[C@@H](C)CC)C(N1CCOCC1)=O
|
| InChi Key |
PLVGDGRBPMVYPB-FDUHJNRSSA-N
|
| InChi Code |
InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1
|
| Chemical Name |
(3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
|
| Synonyms |
GSK221,149; GSK 221,149; GSK-221,149; GSK221149; GSK 221149; GSK-221149; Retosiban; GSK221149A; GSK 221149A; GSK-221149A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~202.2 mM )
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0219 mL | 10.1096 mL | 20.2192 mL | |
| 5 mM | 0.4044 mL | 2.0219 mL | 4.0438 mL | |
| 10 mM | 0.2022 mL | 1.0110 mL | 2.0219 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01867996 | Completed | Drug: Retosiban Drug: EFZ 600 mg |
Obstetric Labour, Premature | GlaxoSmithKline | June 11, 2013 | Phase 1 |
| NCT02377414 | Completed | Drug: Placebo Drug: Retosiban solution for Infusion |
Obstetric Labour, Premature | GlaxoSmithKline | March 2, 2015 | Phase 1 |
| NCT01702376 | Completed | Drug: Retosiban 100 mg Drug: Retosiban 800 mg Drug: Placebo |
Obstetric Labour, Premature | GlaxoSmithKline | October 3, 2012 | Phase 1 |
| NCT02292784 | Completed | Drug: Retosiban Drug: Atosiban Drug: Placebo |
Obstetric Labour, Premature | GlaxoSmithKline | June 1, 2015 | Phase 3 |
| NCT00404768 | Completed | Drug: GSK221149A Drug: Placebo |
Obstetric Labour, Premature | GlaxoSmithKline | October 12, 2007 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA